<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585727</url>
  </required_header>
  <id_info>
    <org_study_id>2007-012</org_study_id>
    <secondary_id>KN 930/1-1</secondary_id>
    <nct_id>NCT01585727</nct_id>
  </id_info>
  <brief_title>Intraoperative Monitoring of the Pelvic Autonomic Nerves</brief_title>
  <acronym>NEUROS</acronym>
  <official_title>Continuous Intraoperative Monitoring of the Pelvic Autonomic Nerves During Total Mesorectal Excision (TME) for the Prevention of Urogenital and Anorectal Dysfunction in Patients With Rectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the major problems of rectal cancer surgery is pelvic autonomic nerve damage, which is
      the main cause of urogenital dysfunction influencing postoperative quality of life. Costs for
      diagnostics and treatment of short and long-term urogenital dysfunction are immense. Varying
      degrees of urogenital dysfunction are found in up to 32% and 55% of patients with rectal
      cancer despite potentially nerve-sparing total mesorectal excision (TME).

      The study will examine the impact of a newly developed continuous monitoring device for
      preservation of urogenital function in patients with TME for rectal cancer. 188 patients will
      be included in the prospective, randomized, single-blind, parallel group multi-centre trial
      including two arms (TME with and without intraoperative continuous monitoring of pelvic
      autonomic nerves). The primary efficacy endpoint is the change in urinary function measured
      by International Prostate Function Score (IPSS) 12 months after surgery. Genital functions
      measured as secondary endpoints. The application of the continuous intraoperative
      neuromonitoring device could enhance the objective intraoperative confirmation of pelvic
      nerve sparing surgery. The investigators hypothesis is that the use of his device minimizes
      the risk of postoperative urogenital dysfunction in patients with TME for rectal cancer. An
      enormous reduction of treatment costs is to be expected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urogenital function</measure>
    <time_frame>12 months</time_frame>
    <description>Increase of IPSS score by at least 5 points observed 12 months after surgery compared to the preoperative IPSS score per patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual function (females)</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of FSFI score by at least 8 points 12 months after surgery compared to the preoperative FSFI score per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function (males)</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of IIEF score by at least 15 points 12 months after surgery compared to the preoperative IIEF score per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological safety</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of pCRM-positive specimen (distance of tumour from circumferential resection margin (CRM) ≤ 1mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of mesorectal excision</measure>
    <time_frame>1 day after the surgery</time_frame>
    <description>Macroscopic assessment of the resection specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal incontinence</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of fecal incontinence using the Wexner-Vaizey score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>TME with neuromonitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TME without neuromontoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>TME with neuromonitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>TME without neuromontoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neuromonitoring</intervention_name>
    <description>Intraoperative neuromonitoring of pelvic autonomic nerves.</description>
    <arm_group_label>TME with neuromonitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  histologically confirmed carcinoma of the rectum (≤ 16 cm from anal verge)

          -  fit for radical surgery

          -  total mesorectal excision

          -  age 18-80 years

        Exclusion Criteria:

          -  history of operation of the urinary tract (e.g. prostatectomy)

          -  pacemaker

          -  emergency operation

          -  multivisceral resection in the pelvis

          -  partial mesorectal excision

          -  eligibility for local excision (TEM, intestinal wall resection)

          -  ongoing infection or sepsis

          -  severe untreated physical or mental impairment

          -  pregnancy or breastfeeding

          -  women of childbearing potential who are not using a highly effective birth control
             method

          -  missing preoperative data on urogenital or anorectal function

          -  simultaneous participation in another clinical trial

          -  previous participation in this clinical trial

          -  lack of cooperation with the trial procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Kneist, Univ.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Visceral and Abdominal Surgery, University Medical Center Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Werner Kneist, Univ.-Prof.</last_name>
    <phone>+496131172483</phone>
    <email>kneist@ach.klinik.uni-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Kauff, Dr. med.</last_name>
    <phone>+496131175912</phone>
    <email>daniel.kauff@web.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of General and Visceral Surgery, University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Kneist, Univ.-Prof.</last_name>
      <phone>+496131172483</phone>
      <email>kneist@ach.klinik.uni-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Kauff, Dr. med.</last_name>
      <phone>+496131175912</phone>
      <email>daniel.kauff@web.de</email>
    </contact_backup>
    <investigator>
      <last_name>Werner Kneist, Univ.-Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Kauff, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Werner Kneist</investigator_full_name>
    <investigator_title>Senior physician, Department of Visceral and Abdominal Surgery</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>total mesorectal excision</keyword>
  <keyword>pelvic autonomic nerve preservation</keyword>
  <keyword>neurostimulation</keyword>
  <keyword>urogenital function</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

